POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

被引：1

作者：

Golan, T. ^{[1
]}

Hammel, P. ^{[2
]}

Reni, M. ^{[3
]}

Van Cutsem, E. ^{[4
]}

Mercade, T. Macarulla ^{[5
]}

Hall, M. J. ^{[6
]}

Park, J. O. ^{[7
]}

Hochhauser, D. ^{[8
]}

Arnold, D. ^{[9
]}

Oh, D-Y. ^{[10
]}

Reinacher-Schick, A. ^{[11
]}

Tortora, G. ^{[12
]}

Algul, H. ^{[13
]}

O'Reilly, E. M. ^{[14
]}

Bordia, S. ^{[15
]}

McGuinness, D. ^{[16
]}

Cui, K. Y. ^{[17
]}

Locker, G. ^{[18
]}

Kindler, H. ^{[19
]}

机构：

[1] Inst Oncol, Sheba Med Ctr, Oncol, Ramat Gan, Israel

[2] Hop Paul Brousse Assistance Publiquee Hopitaux Pa, Oncol, Villejuif, France

[3] Ist Sci San Raffaele, Med Oncol, IRCCS Osped, Milan, Italy

[4] Univ Hosp Gasthuisberg & KU Leuven, Digest Oncol, Leuven, Belgium

[5] Vall dHebron Univ Hosp, Med Oncol, Vall dHebron Inst Oncol, Barcelona, Spain

[6] Fox Chase Canc Ctr, Clin Genet, Philadelphia, PA USA

[7] Sungkyunkwan Univ, Samsung Med Ctr, Med Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] UCL Canc Inst, Oncol, Paul OGorman Bldg, London, England

[9] Asklepios Tumorzentrum Hamburg AK Altona, Oncol Haematol, Palliat Care, Hamburg, Germany

[10] Seoul Natl Univ Hosp, Canc Res Inst, Med, Seoul, South Korea

[11] Ruhr Univ Bochum, Hematol, Oncol & Palliat Care, St Josef Hosp, Bochum, Germany

[12] Fondazione Policlin Gemelli IRCCS, Med Oncol, Rome, Italy

[13] Comprehens Canc Ctr Munich TUM, Tech Univ, Internal Med 2, Klinikum Rechts Isar, Munich, Germany

[14] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[15] Merck Co Inc, Oncol Late Dev, Kenilworth, NJ USA

[16] Biometr & Informat Sci, Astrazeneca UK, Cambridge, England

[17] Late Dev Oncol, Oncol R, Astrazeneca US, Gaithersburg, MD USA

[18] GI Canc Drug Dev, Astrazeneca US Time Study, Gaithersburg, MD USA

[19] Univ Chicago, Med Sect Hematol Oncol, Chicago, IL USA

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.796

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1468P

引用

页码：S1086 / S1087

页数：2

共 50 条

[31] POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).
Schwartz, Lawrence Howard
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen Mary
Fromageau, Jeremie
Ghiorghiu, Dana C.
McGuinness, David
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[32] Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Li, Na
Zheng, Huanrui
Huang, Yanlei
Zheng, Bin
Cai, Hongfu
Liu, Maobai
FRONTIERS IN PHARMACOLOGY, 2021, 12
[33] Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P)
Macarulla, Teresa
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[34] Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Mercade Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Alguel, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
[35] Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
Hall, Michael J.
Golan, Talia
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke C.
Tortora, Giampaolo
Algul, Hana
O'Reilly, Eileen Mary
McGuinness, David
Cui, Karen
Joo, Seongjung
Yoo, Hyun Kyoo
Patel, Nikunj
Kindler, Hedy L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[36] Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation (gBRCAm): Phase III POLO trial
Arnold, D.
Hall, M. J.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Park, J. O.
Hochhauser, D.
Oh, D-Y
Reinacher-Schick, A.
Tortora, G.
Algul, H.
O'Reilly, E.
McGuiness, D.
Cui, K.
Joo, S.
Yoo, H. K.
Patel, N.
Kindler, H.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 217 - 217
[37] Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (vol 377, pg 523, 2017)
Robson
Im
Senkus
Domchek
Masuda
Tung
Armstrong
Wu
Goessl
Runswick
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (17): : 1700 - 1700
[38] Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Alguel, Hana
O'Reilly, Eileen M.
Bordia, Sonal
McGuinness, David
Cui, Karen
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3929 - +
[39] A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation
Wang, Huan
Mao, Chenyu
Li, Ning
Sun, Liping
Zheng, Yulong
Xu, Nong
MEDICINE, 2019, 98 (40)
[40] Maintenance Olaparib for Metastatic Pancreatic Cancer
Charkes, N. David
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (15): : 1491 - 1491

← 1 2 3 4 5 →